EpiPen Says It Can ‘Meet Any Anticipated Demand’ for Auto-Injectors Due to Recall

in Recalls
Published: October 29, 2015

Mylan Specialty, the company that markets the EpiPen and EpiPen Jr. epinephrine auto-injectors in the United States, released a statement Oct. 29 assuring the public that its products are not part of the U.S.-wide recall of all Auvi-Q auto-injectors by Sanofi US.

In addition to not being part of the recall, the EpiPen manufacturer noted that it “has sufficient supply of EpiPen® Auto-Injector to meet any anticipated demand.”

“Mylan is working to provide a seamless transition for patients and their caregivers who may now be prescribed EpiPen Auto-Injector,” said Heather Bresch, Mylan’s CEO, in the release.

Read Mylan’s full release here.

In Canada, there is also a full recall of the Sanofi auto-injector, sold under the brand name Allerject. Read about short-term epinephrine supply issues in Canada here.